



June 10, 2022

To

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400 001
Tel: 022 - 2272 1233 /4
Fax: 022 - 22721919

Ref: Aragen Life Sciences Private Limited

Scrip Code: 973783

ISIN: INE483I07010

Sub: Intimation of approval of the Composite Scheme of Arrangement between Excelra Knowledge Solutions Private Limited, GVK Davix Technologies Private Limited, GVK Davix Research Private Limited and Aragen Life Sciences Private Limited and their respective shareholders, by the Hon'ble National Company Law Tribunal, Hyderabad Bench.

We hereby inform that the joint petition filed with the Hon'ble National Company Law Tribunal (NCLT), Hyderabad Bench, under Sections 230-232 of Companies Act, 2013, by the afore-cited companies, seeking sanction of the Composite Scheme of Arrangement between Excelra Knowledge Solutions Private Limited, GVK Davix Technologies Private Limited, GVK Davix Research Private Limited and Aragen Life Sciences Private Limited and their respective shareholders ("Scheme"), was duly approved by the NCLT, Hyderabad Bench through its order dated 30th May, 2022, of which a certified copy has been received by the Company on the 7th June 2022. The Order of the NCLT, Hyderabad Bench, was taken note by the Board of Directors of the Company on 09th June, 2022.

Pursuant to the Scheme, the Remaining Business Undertaking of GVK Davix Technologies Private Limited, the holding company of the Company, with only investment in Aragen Life Sciences Private Limited, amalgamates with the Company.

The implementation of the Scheme will have no bearing on the performance/operations of the Company.

This is for your information and records.

For Aragen Life Sciences Private Limited

Ramakrishna Kasturi



Company Secretary & Compliance Officer.

Registered & Corporate Office
Aragen Life Sciences Pvt. Ltd.
(Formerly known as GVK Biosciences Pvt. Ltd.)
28 A, IDA Nacharam, Hyderabad 500 076, India
T: +91 40 6692 9999 F: +91 40 6692 9900
W: aragen.com CIN: U74999TG2000PTC035826